{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI.&page=7", "query": { "intervention": "FOLFIRI.", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 172, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI.&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI.&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T13:00:44.548Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04587128", "title": "Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2020-10-19", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04587128" }, { "nct_id": "NCT00020488", "title": "Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020488" }, { "nct_id": "NCT01320683", "title": "Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Metastases", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2011-03", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-07-19", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01320683" }, { "nct_id": "NCT00443573", "title": "Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "recombinant nematode anticoagulant protein c2 (rNAPc2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ARCA Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-05-07", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00443573" }, { "nct_id": "NCT00020501", "title": "Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "floxuridine", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "hyperthermia treatment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-03", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020501" }, { "nct_id": "NCT00813605", "title": "QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI", "type": "OTHER" }, { "name": "AMG 655", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "AMG 479", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "NantCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2009-03", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2016-10-27", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 28, "location_summary": "Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00813605" }, { "nct_id": "NCT06011772", "title": "EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Colo-rectal Cancer" ], "interventions": [ { "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Metastasectomy", "type": "PROCEDURE" }, { "name": "Biospecimen collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Panitumumbab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-12-18", "completion_date": "2029-02-05", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06011772" }, { "nct_id": "NCT07861386", "title": "Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer (mCRC)" ], "interventions": [ { "name": "FOLFIRI plus bevacizumab", "type": "DRUG" }, { "name": "mFOLFOX6 plus bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9978, "start_date": "2026-08-20", "completion_date": "2026-10-20", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 1, "location_summary": "Somerville, Massachusetts", "locations": [ { "city": "Somerville", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07861386" }, { "nct_id": "NCT00719199", "title": "Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "IMO-2055", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2009-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2013-10-22", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719199" }, { "nct_id": "NCT05332002", "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro-Intestinal Cancer" ], "interventions": [ { "name": "Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2022-07-13", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-10T13:00:44.548Z", "location_count": 6, "location_summary": "Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05332002" } ] }